Effect of newer antihyperglycemic drugs on liver steatosis indices in patients with diabetes and obesity-Reference-Cited by-同舟云学术

Effect of newer antihyperglycemic drugs on liver steatosis indices in patients with diabetes and obesity

Published:2021-08-28 Issue:11 Volume:37 Page:1867-1873
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Carretero Gómez Juana¹,Ena Javier²,Seguí Ripoll José Miguel³,Carrasco-Sánchez Francisco Javier⁴^ORCID,Gómez Huelgas Ricardo⁵⁶,Casas Rojo José Manuel⁷,Suárez Tembra Manuel⁸,Carabantes Rueda Juan Jesús⁹,Arévalo Lorido José Carlos¹^ORCID

Affiliation:

1. Internal Medicine Department, University Hospital of Badajoz, Badajoz, Spain

2. Internal Medicine Department, Marina Baixa Hospital, La Vila Joiosa, Alicante, Spain

3. Internal Medicine Department, San Juan de Alicante University Hospital, Alicante, Spain

4. Internal Medicine Department, Juan Ramón Jimenez University Hospital, Huelva, Spain

5. Internal Medicine Department, Regional University Hospital of Málaga, Málaga, Spain

6. Institute of Biomedical Research in Malaga (IBIMA), CIBER Physiopathology of Obesity and Nutrition – CIBERobn, Malaga, Spain

7. Internal Medicine Department, Infanta Cristina University Hospital, Parla, Spain

8. Internal Medicine Department, San Rafael General Hospital, A Coruña, Spain

9. Internal Medicine Department, Antequera General Hospital, Málaga, Spain

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2021.1965563

Reference36 articles.

1. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

2. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease

3. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases

4. Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease

5. Design and validation of a histological scoring system for nonalcoholic fatty liver disease

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic dysfunction-associated steatotic liver disease - A new indication for sodium-glucose Co-transporter-2 inhibitors;Advances in Medical Sciences;2024-09

2. Efecto de semaglutida sobre los biomarcadores de la enfermedad del hígado graso en pacientes con diabetes y obesidad;Revista Clínica Española;2023-03

3. Effect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity;Revista Clínica Española (English Edition);2023-03

4. Economic Burden of Non-Alcoholic Steatohepatitis (NASH) Among Diabetic Population in Italy: Analysis and Perspectives;ClinicoEconomics and Outcomes Research;2022-09